Targeted Therapy Has New Target - Pain dailyRx As one of the first targeted therapies, Gleevec (imatinib) totally changed the care and outlook for people diagnosed with chronic myeloid leukemia (CML). With a bit of tweaking, this drug may be used to treat another chronic condition - pain.
New Lawsuit Filed on Benzene Leukemia: AttorneyOne.com Provides Advice and ... Albany Times Union Mr. Dorsey accuses DuPont De Nemours, Exxon Mobil Corp. and some of its subsidiaries, Foster Wheeler Energy Corp., Gulf Oil Corp., Texaco, US Steel, Chevron USA, and 4520 Corp. alleging that he developed leukemia from benzene exposure.
Bone Marrow Drive Held For Local Firefighter KGTV San Diego In 2007, Ortanez was diagnosed with chronic myelogenous leukemia, or leukemia CML. It is a type of cancer that affects white blood cells. "I always kept it to myself … [but] where I'm at right now, it's like I'm running out of options," the 41-year ...
Nilotinib Continues To Produce Deep Response in Patients Clinical Oncology News About 40% of imatinib-treated patients with chronic phase chronic myeloid leukemia (CML-CP) who achieve durable complete molecular response (CMR) are able to discontinue therapy without recurrence. However, the remaining majority of patients with CML ...
ARIAD Announces Issuance of Key U.S. Patent on Ponatinib EON: Enhanced Online News (press release) BCR-ABL is an abnormal tyrosine kinase that is expressed in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Using ARIAD's computational and structure-based drug design platform, ...
Therapy targets leukemia stem cells EurekAlert (press release) Chronic myelogenous leukemia (CML) is a cancer of the white blood cells for which tyrosine kinase inhibitors are currently the first line of therapy. These drugs prolong survival, but disease recurrence is often seen after drug treatment is stopped.
Outwitting Chronic Myeloid Leukemia dailyRx About 20 percent of all leukemias in the Western world are chronic myeloid leukemia (CML). Today's treatments target an abnormal chromosome that causes the disease, but new theories about how to outwit this resilient disease are sprouting.
